Press release
Chronic Kidney Disease Clinical Trial Pipeline | 75+ Companies Pioneering the Future of Treatment
Major pharmaceutical companies are working to advance the pipeline space and unlock the future growth potential of the Chronic Kidney Disease treatment landscape.DelveInsight's 'Chronic Kidney Disease Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Chronic Kidney Disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Chronic Kidney Disease pipeline domain.
For Chronic Kidney Disease emerging drugs, the Chronic Kidney Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Kidney Disease Pipeline Report
• DelveInsight's Chronic Kidney Disease Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Chronic Kidney Disease treatment.
• The leading Chronic Kidney Disease companies include AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals, ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, KBP Biosciences, Kibow Pharma, Cincor Pharma, Lexicon Pharmaceuticals, Sanofi, and others are evaluating their lead assets to improve the Chronic Kidney Disease treatment landscape.
• Key Chronic Kidney Disease pipeline therapies in various stages of development include Renal Autologous Cell Therapy, Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE, KBP-5074, KT-301, CIN-107, Zibotentan, ALLN-346, DM199, DM199, and others.
• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.
• On November 11, 2024, Unicycive Therapeutics announced that the U.S. FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a PDUFA target action date of June 28, 2025. If approved, OLC could significantly improve treatment for hyperphosphatemia in Chronic Kidney Disease patients on dialysis.
Request a sample and discover the recent breakthroughs happening in the Chronic Kidney Disease pipeline landscape @ https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a progressive condition in which the kidneys become damaged and lose their ability to effectively filter blood. As a result, excess fluid and waste accumulate in the body, increasing the risk of serious health complications such as heart disease and stroke. CKD varies in severity, typically worsening over time. While there is no cure, timely treatment can slow its progression. If left unmanaged, CKD can lead to kidney failure and an increased risk of cardiovascular disease.
In its early stages (Stages 1-3), CKD often goes unnoticed, as many patients experience no symptoms. It is usually detected through estimated glomerular filtration rate (eGFR) tests before any noticeable signs develop. Symptoms generally emerge in more advanced stages (Stage 4 or beyond) and may include fatigue, low energy levels, and an overall sense of feeling unwell.
CKD occurs due to a gradual decline in kidney function, resulting in damage to the kidneys. As the disease progresses, the remaining functional glomeruli adapt and compensate to maintain normal kidney function for as long as possible. However, this adaptation leads to increased pressure and hyperfiltration, triggering the release of cytokines and growth factors, which cause hypertrophy and hyperplasia. Over time, the excessive strain on the glomeruli results in increased permeability and proteinuria, with elevated protein levels in the proximal tubules further exacerbating kidney damage.
Since CKD often presents no symptoms in its early stages, routine testing is essential for early detection. Blood and urine tests are commonly used to assess kidney function, measuring levels of compounds such as GFR and protein, which indicate kidney impairment. Higher values in these tests typically suggest more severe CKD.
While CKD has no definitive cure, various treatments can help manage symptoms and slow disease progression. The treatment approach depends on the disease stage and focuses on preserving kidney function. Medications can help control underlying conditions contributing to CKD, such as diabetes, high blood pressure, high cholesterol, and anemia. Kidney transplant recipients, who represent a subset of CKD patients, remain at high risk of disease progression and require careful management. Although advances in immunosuppressive therapies have improved transplant outcomes, long-term graft survival and patient prognosis remain key challenges.
Find out more about Chronic Kidney Disease medication @ https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Kidney Disease Treatment Analysis: Drug Profile
Baxdrostat : AstraZeneca
Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.
Ziltivekimab: Novo Nordisk
Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.
BI-685509: Boehringer Ingelheim
BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.
PXL770: Poxel SA
PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.
Key Chronic Kidney Disease Therapies and Companies
• Baxdrostat : AstraZeneca
• Ziltivekimab: Novo Nordisk
• BI-685509: Boehringer Ingelheim
• PXL770: Poxel SA
• Renal Autologous Cell Therapy (REACT): ProKidney
• Bardoxolone methyl: Reata Pharmaceuticals, Inc.
• Ziltivekimab: Novo Nordisk A/S
• Semaglutide: Novo Nordisk A/S
• JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly and Company
• KBP-5074: KBP Biosciences
• KT-301: Kibow pharma
• CIN-107 (Baxdrostat): Cincor Pharma
• Zibotentan: AstraZeneca
• ALLN-346: Allena Pharmaceuticals
• DM199: DiaMedica Therapeutics Inc
• Sotagliflozin: Lexicon Pharmaceuticals/Sanofi
Learn more about the novel and emerging Chronic Kidney Disease pipeline therapies @ https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Kidney Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Chronic Kidney Disease Pipeline Report
• Coverage: Global
• Key Chronic Kidney Disease Companies: AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals, ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, KBP Biosciences, Kibow Pharma, Cincor Pharma, Lexicon Pharmaceuticals, Sanofi, and others.
• Key Chronic Kidney Disease Pipeline Therapies: Renal Autologous Cell Therapy, Bardoxolone methyl, Ziltivekimab, Semaglutide, JARDIANCE, KBP-5074, KT-301, CIN-107, Zibotentan, ALLN-346, DM199, DM199, and others.
Dive deep into rich insights for drugs used for Chronic Kidney Disease treatment; visit @ https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Kidney Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Kidney Disease Pipeline Therapeutics
6. Chronic Kidney Disease Pipeline: Late-Stage Products (Phase III)
7. Chronic Kidney Disease Pipeline: Late-Stage Products (Phase III)
8. Chronic Kidney Disease Pipeline: Mid-Stage Products (Phase II)
9. Chronic Kidney Disease Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Kidney Disease Clinical Trial Pipeline | 75+ Companies Pioneering the Future of Treatment here
News-ID: 3888538 • Views: …
More Releases from DelveInisight Business Research

Rotator Cuff Injuries Market Poised for Significant Growth by 2032, Driven by In …
The rotator cuff injuries treatment market is expected to witness substantial growth across the 7MM (United States, EU4, United Kingdom, and Japan) by 2032, primarily fueled by an increasing prevalence of rotator cuff disorders, a rising aging population, advancements in minimally invasive surgical techniques, and the emergence of novel biologic therapies aimed at enhancing tendon healing and regeneration. Key rotator cuff repair companies, including Ortho Regenerative Technologies, Angiocrine Bioscience, Smith…

Cancer Pain Management Market is Expected to Grow Significantly by 2034, Driven …
DelveInsight's "Cancer Pain Market Insight, Epidemiology and Market Forecast - 2034" [https://www.delveinsight.com/report-store/cancer-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers an in-depth understanding of the cancer pain therapeutic landscape, including historical and forecasted epidemiology alongside current and emerging market trends across the 7MM (United States, EU4, United Kingdom, and Japan). The cancer pain market is expected to grow significantly with a decent CAGR through 2034. This growth is underpinned by several market drivers, including the increasing…

Diabetic Foot Ulcers Pipeline 2025: Mechanism of Action, Route of Administration …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…

Alpha-1 Antitrypsin Deficiency Pipeline 2025: FDA Updates, Therapy Innovations, …
Alpha-1 Antitrypsin Deficiency pipeline constitutes 12+ key companies continuously working towards developing 12+ Alpha-1 Antitrypsin Deficiency treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Alpha-1 Antitrypsin Deficiency Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha-1 Antitrypsin Deficiency Market.
The Alpha-1 Antitrypsin Deficiency Pipeline report embraces in-depth commercial…
More Releases for Kidney
Surging Chronic Kidney Cases Propel Growth In The Artificial Kidney Market: Tran …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Artificial Kidney Industry Market Size Be by 2025?
The market size for artificial kidneys has experienced swift expansion in the latest years. The market is predicted to escalate from $10.22 billion in 2024 to $11.43 billion in 2025, with a compound annual growth rate (CAGR) of…
Chronic Kidney Diseases Fueling Kidney Stone Retrieval Device Growth Driving Mar …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Kidney Stone Retrieval Devices Market Size By 2025?
In recent times, the market size for kidney stone retrieval devices has seen consistent growth. The market, which is projected to increase from $2.84 billion in 2024 to $2.96 billion in 2025, forecasts a compound annual growth…
Wearable Artificial Kidney Market Development Trajectory through 2031 Dutch Kidn …
"[New York, December 2024] The Wearable Artificial Kidney represents a groundbreaking innovation in nephrology that combines advanced biomedical engineering with portable technology. Designed to continuously filter waste from the blood, this device caters primarily to patients with chronic kidney disease. As renal health issues become more prevalent globally, the relevance of the Wearable Artificial Kidney lies in its potential to enhance patient quality of life, providing a more convenient and…
Kidney Dialysis Market Share Kidney Dialysis Market
According to Ameco Research 'Kidney Dialysis Market report, the analysts took this into account when estimating the Kidney Dialysis Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the Kidney Dialysis Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes Kidney Dialysis Market trends, segmentation, key…
Kidney Health Journey: Polycystic Kidney Disease Drug Pipeline Landscape (2023-2 …
Market Outlook:
The Polycystic Kidney Disease (PKD) drug pipeline landscape is poised for noteworthy advancements, offering a positive outlook for those navigating the complex journey of kidney health. As PKD poses a significant global health burden, the market outlook reflects a pressing need for innovative pharmaceutical interventions to address the challenges associated with this genetic disorder. With ongoing research and development efforts, the PKD drug pipeline is positioned to bring…
Kidney Balloon Market Growth Drives By Rising Prevalence of Kidney Stone and Oth …
Demand Analysis of Kidney Balloon Market Overview:
Kidney Balloon Market is predicted to grow at a moderate CAGR of 5.2% during the forecast period covering 2022 to 2029. Kidney Balloon Market share is estimated to reach a value of nearly US$ 2.50 Billion by 2029.
The "Kidney Balloon Market" think about 2022, the industry landscape is secured from driving factors to upstream markets and the by and large state of the market.…